Healthcare M&A’s Next Constraint Depends on Who You Ask

Healthcare M&A may be entering a more active period, but the obstacles to getting deals done are becoming increasingly fragmented. A proprietary Healthcare150 survey of 69 respondents asked what would constrain healthcare M&A activity most over the next 12 months. The results show little consensus across functions. Instead, clinical leaders, finance executives, and operators are identifying fundamentally different risks, suggesting that the next constraint on deal activity may come from inside the investment committee as much as from the external market.

The sharpest concern among clinical and healthcare leadership is regulatory uncertainty. 50% of respondents in this group selected regulation as the largest constraint, compared with 21% citing integration risk and just 14% each selecting financing costs and valuations. That concern is consistent with the broader operating environment. Deloitte found that 80% of surveyed healthcare executives expected regulatory and policy factors to influence their strategies in 2026, while 43% described themselves as uncertain or neutral about the industry's near-term outlook. Deloitte

For finance, investment, and corporate strategy executives, however, the equation looks almost inverted. 50% identify financing costs as the principal constraint, while only 6% point to regulatory uncertainty. Integration risk accounts for 25%, and valuations for 19%. This suggests that capital availability alone is not sufficient to restart transaction volumes. Buyers still need transaction economics capable of absorbing financing costs while producing acceptable returns, particularly when reimbursement, labor, and other operating pressures can make future EBITDA less predictable.

There are signs that those financing conditions are becoming more supportive. PwC entered 2026 expecting lower interest rates, private equity dry powder, and pressure to generate liquidity to help release a backlog of transactions delayed during the previous cycle. Yet the firm also warned that valuation dislocation and uncertainty around reimbursement, drug pricing, and digital health regulation could continue constraining middle-market activity. PwC The implication is that cheaper or more available capital can reopen the door, but it does not automatically make an asset financeable at the seller's preferred price.

Operations and technology executives introduce a third constraint. Integration risk ranks first for this group at 33%, ahead of regulatory uncertainty at 27%, while financing costs and valuations each account for 20%. Their concern points toward what happens after a transaction closes. Healthcare assets increasingly combine complex clinical workflows, technology infrastructure, reimbursement arrangements, workforces, and data environments. The financial case for consolidation can therefore deteriorate quickly if integration costs are underestimated or anticipated synergies take longer to materialize.

Current deal activity reinforces that shift toward execution. PwC's 2026 midyear health services outlook says buyers are scrutinizing integration feasibility, payer mix, compliance exposure, and labor resilience earlier in the transaction process. The firm describes a selective market in which capital remains available but increasingly favors scalable assets with durable margins and clear value creation pathways. PwC Deloitte similarly reports growing healthcare interest in transactions, with 59% of surveyed healthcare finance leaders saying M&A would increase as an organizational priority in 2026, up from 42% in its 2025 CFO study. Deloitte

Perhaps the most revealing finding in the Healthcare150 survey is what respondents do not identify as the dominant problem. Valuations receive only 14% to 20% across the three groups and do not rank first for any constituency. That does not mean pricing has ceased to matter. Rather, it suggests that valuation is increasingly being assessed alongside a broader set of risks that determine whether the headline purchase price can ultimately generate the expected return.

For healthcare executives and investors, this changes the M&A conversation. A transaction can clear the valuation hurdle and still stall because clinicians see regulatory exposure, finance teams cannot make the capital structure work, or operators doubt the integration plan. The next phase of healthcare M&A may therefore be defined less by whether buyers want to transact and more by whether organizations can align those competing definitions of risk before signing.

Bottom line: Healthcare M&A does not appear to have a single market-wide bottleneck. The constraint changes depending on who is underwriting the deal, making internal alignment on regulation, financing, and integration increasingly important to transaction certainty.